anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To improve the storage stability, curability at a deep inside, and hydrophilicity of a cured item by compounding two specific polyether, a fatty acid ester of a polyhydric alcohol, and a catalyst selected from the group consisting of platinum, a platinum complex, and chloroplatinic acid. CONSTITUTION:The title compsn. comprises a linear or branched polyether having a mol.wt. of pref. 200 or higher and terminal alkenyl groups, a linear or branched polyether having at least two Si-H groups per molecule, and at least one terminal polyorganosiloxane residue having at least one Si-H group, and contg. Si-H groups in anamt. of 0.5-10mol per mol of total alkenyl groups in the compsn 0.1-30wt.% fatty acid ester of a polyhydric alcohol, and a catalyst selected from the group consisting of platinum, a platinum complex, and chloroplatinic acid in an amt. of 0.1ppm to 5wt.% in terms of Pt based on the sum of the two polyethers.
BACKGROUND: Superficial siderosis (SS) of the central nervous system is a rare disease characterized by deposition of hemosiderin along the leptomeninges due to chronic or recurrent bleeding into the subarachnoid space. The association of unruptured intracranial aneurysm (IA) and cortical SS is quite rare.
METHODS: A systematic literature review to assess possible commonalities and/or differences of previous reported cases was undertaken. We report an additional case from our institution.
RESULTS: A 40-year-old woman presented with a history of generalized seizures over the past year. There was no clinical history suggestive of aneurysm rupture. Magnetic resonance imaging revealed 2 aneurysms of the right middle cerebral artery (MCA) bifurcation associated with hemosiderin deposition along the right sylvian fissure and a third aneurysm of the left MCA bifurcation. Magnetic resonance imaging showed wall enhancing thickening of the larger right MCA aneurysm. The patient underwent surgical clipping of all 3 MCA aneurysms in a staged procedure. Histological examination revealed hemosiderin deposits within the aneurysm wall and surrounding gliosis.
CONCLUSIONS: Our literature review found 24 reported cases of unruptured IA associated with cortical SS. The possible source for leakages could be neovessels visible in IA walls. The case reported illustrates an uncommon presentation of recurrent bleeding from an IA as a source of SS. The presence of an apparently unruptured IA surrounded by cortical SS on imaging studies is of high relevance as this should be considered a sign of aneurysm wall instability and should indicate prompt treatment.
Amyotrophic lateral sclerosis (ALS) is characterised primarily by motor system degeneration, with clinical evidence of cognitive and behavioural change in up to 50% of cases. We have shown previously that resting-state EEG captures dysfunction in motor and cognitive networks in ALS. However, the longitudinal development of these dysfunctional patterns, especially in networks linked with cognitive-behavioural functions, remains unclear. Longitudinal studies on non-motor changes in ALS are essential to further develop our understanding of disease progression, improve care and enhance the evaluation of new treatments. To address this gap, we examined 124 ALS individuals with 128-channel resting-state EEG recordings, categorised by cognitive impairment (ALSci, n = 25), behavioural impairment (ALSbi, n = 58), or non-impaired (ALSncbi, n = 53), with 12 participants meeting the criteria for both ALSci and ALSbi. Using linear mixed-effects models, we characterised the general and phenotype-specific longitudinal changes in brain network, and their association with cognitive performance, behaviour changes, fine motor symptoms, and survival. Our findings revealed a significant decline in [Formula: see text]-band spectral power over time in the temporal region along with increased [Formula: see text]-band power in the fronto-temporal region in the ALS group. ALSncbi participants showed widespread β-band synchrony decrease, while ALSci participants exhibited increased co-modulation correlated with verbal fluency decline. Longitudinal network-level changes were specific of ALS subgroups and correlated with motor, cognitive, and behavioural decline, as well as with survival. Spectral EEG measures can longitudinally track abnormal network patterns, serving as a candidate stratification tool for clinical trials and personalised treatments in ALS.
In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
Inclusion criteria are subjects requiring a bone defect between 3 to 8 millimeters (moderate to severe bone defect) covered 1-2 tooth span with adjacent tooth, planned for dental implant and fixed prosthesis, aged 20 and above but under the age of 65 with good physical health and good oral hygiene, able to comprehend and are willing to sign the consent form and can adhere to the protocol including scheduled clinic visits and assigned treatment and available for follow-up after implant placement.

Exclusion criteria are subjects in following reasons: (i) Heavy smokers (\>10 cigarettes/day), (ii) receiving bisphosphonates, (iii) undergoing radiotherapy, (iv) uncontrolled medical conditions, (v) Alcoholism, (vi) Pregnancy Bone augmentation procedure Before surgery, patients will be premedication with 1000 mg of amoxicillin antibiotic and rinse chlorhexidine mouthwash 0.12% concentration for 1 minute. A single oral and maxillofacial surgeon will perform all surgical procedures. Local anesthesia with 4% Articaine hydrochloride with epinephrine 1: 100,000 (Septanest, Septodont, France) will be administered to each patient for inferior alveolar nerve block or local infiltration. A full thickness mucoperiosteal flap will be created, and the actual defect size will be measured with a periodontal probe following the flap procedure. Flap advancement with periosteal releasing flap, decorticate the bone with a round bur, then apply the semi-rigid shell and fix it with ti-tacks or screws. Following that, xenograft, a bone graft material will be placed, and ti-tacks will be used to fix the semi-resorbable covering membrane. Lastly, tension-free flap closure with double layer suturing technique which is a horizontal mattress and interrupts suture.
Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans each year. Schizophrenia can be extremely disabling, causing people to hear voices, experience paranoia or hallucinations, and believe that others are controlling their thoughts. Many people with schizophrenia have difficulty with remembering their scheduled doctor's appointments and with taking their medication on time because of their mental illness. Many approved medications for schizophrenia must be taken several times a day and side effects such as drowsiness, dizziness, and even weight gain can deter a person from consistently taking their medication on time. Therefore, this study will determine whether a 2-way pager will help people with schizophrenia to remember their doctor's appointments and to take their medication on time.

Participants in this open-label study will first complete several written tests to assess skills such as memory, attention, and problem solving. Participants will also be asked questions regarding their current symptoms and medication regimen. Participants will then be randomly assigned to receive either treatment as usual or treatment as usual and a 2-way pager for 6 months. Participants who receive a 2-way pager will attend approximately four information sessions. During these sessions, participants will learn how to program the pager and use a specially designed medication bottle cap that will record the number of bottle openings and the date and time of each opening. At designated times, the pager will vibrate or beep, alerting participants to take their medication or attend a scheduled appointment. All participants will meet weekly with a staff member for the first month and then once a month for the remaining 5 months to complete several brief questionnaires on pager use, assess medication adherence, and discuss any symptoms experienced within the past week or month. Participants will be required to bring their medication to each meeting to ensure compliance.
PROBLEM TO BE SOLVED: To obtain a selective medicine absorption promoter capable of promoting absorption of an anti-inflammatory medicine and suppressing absorption of a substance not favorable to an organism, such as an antiseptic, etc. SOLUTION: This selective medicine absorption promoter comprises 0.1-10wt.% of an anti-inflammatory medicine and an ether type nonionic surfactant in the same amount as that of the anti-inflammatory medicine to ten times the amount of the anti-inflammatory medicine. The content of the surfactant is 0.1-10wt.% based on the total of the composition in a system. A nonsteroid anti-inflammatory medicine such as tenoxicam, indomethacin, etc., is used as the anti-inflammatory medicine. A polyoxyethylene nonyl phenyl ether is cited as the ether type nonionic surfactant and has 5-18 HLB. The anti-inflammatory medicine composition can be pharmaceutically manufactured into an oral medicine or an injection. Percutaneous administration as a skin preparation for external use is most preferable.  A dose is 0.1-5g/day/adult and administered dividedly several times in the case of oral administration and 0.1-3g/day/adult in the case of an injection. A dose to be uniformly spread to the affected part is applied once to several times as a skin preparation for external use.
Ameliorating the deleterious impact of systemic or tissue-level hypoxia or ischemia is key to preventing or treating many human diseases and pathologies. Usefully, environmental hypoxia is also a common challenge in many natural habitats; animals that are native to such hypoxic niches often exhibit strategies that enable them to thrive with limited O2 availability. Studying how such species have evolved to tolerate systemic hypoxia offers a promising avenue of discovery for novel strategies to mitigate the deleterious effects of hypoxia in human diseases and pathologies. Of particular interest are naked mole-rats, which are among the most hypoxia-tolerant mammals. Naked mole-rats that tolerate severe hypoxia in a laboratory setting are also protected against clinically relevant mimics of heart attack and stroke. The mechanisms that support this tolerance are currently being elucidated but results to date suggest that metabolic rate suppression, reprogramming of metabolic pathways, and mechanisms that defend against deleterious perturbations of cellular signaling pathways all provide layers of protection. Herein, we synthesize and discuss what is known regarding adaptations to hypoxia in the naked mole-rat cardiopulmonary system and brain, as these systems comprise both the primary means of delivering O2 to tissues and the most hypoxia-sensitive organs in mammals.
MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers.
The present invention relates to a preparation method of a snake gallbladder and tangerine peel dispersed tablet, which is characterized in that after the tangerine peel is pulverized into fine powder, the tangerine peel powder is uniformly mixed with the snake gallbladder; the mixture of the tangerine peel powder and the snake gallbladder are dried and pulverized into fine powder; auxiliary materials are added and are uniformly mixed; after direct tablet compression or granulation drying, the compressed tablets or the snake gallbladder is manufactured into dry cream powder by drying and is uniformly mixed with the tangerine peel fine powder and the auxiliary materials, and after direct tablet compression or granulation drying, the tablets are compressed, and the complete set of preparation methods are completed. The snake gallbladder and tangerine peel dispersed tablet is reformed on the technology of the existing preparation. The present invention has the advantages of quick effects, favorable mouth feelings and convenient administration. The present invention is suitable for adults, children and old people; the quality control standard is generally increased, and the present invention well satisfies and guarantees the medication requirements of people. The snake gallbladder and tangerine peel dispersed tablet has the functions of normalizing qi, transforming phlegm, expelling wind and promoting digestion. The snake gallbladder and tangerine peel dispersed tablet is used for the symptoms, such as wind-cold cough, copious phlegm, retching counterflow, etc. The present invention is popular at clinic and is a safe, stable and effective medicine with the advantages of convenient production, carrying and usage, and the present invention is an ideal product of the modern pharmaceutical enterprise.
PURPOSE:To provide a skin-beautifying agent and skin cosmetic containing a specific lavendustin compound as an active component and effective for suppressing the melanogenesis of melanocyte and reducing or eliminating pigmentation caused by the external stimulation such as ultraviolet ray. CONSTITUTION:The skin-beautifying agent and skin cosmetic contains a lavendustin compound of formula (R is H or OH) as an essential component. The cosmetic compounded with the lavendustin of formula has excellent skin- beautifying effect and preventing and treating effect on spots and freckles caused by sunburn, etc. The lavendustin compound of formula can be produced by the cultivation of actinomycetes. The amount of the compound of formula in a skin cosmetic is preferably about 0.0001-5%. It can be used in the form of cream, essence, milky lotion, face lotion, creamy foundation, pack, etc.
Protocol of therapeutic exercises + real transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the EG will perform the RM strengthening exercises while receiving real a-tDCS.
The invention relates to medical products having a surface that is at least partially covered by a polymer layer. Said polymer layer is preferably formed by auto-polymerization. Substances containing least one multiple bond, especially unsaturated fatty acids comprising an alkyl chain consisting of preferably between 7 and 50 carbon atoms are polymerized. Other substances which do not participate in the polymerization can be added to the substances participating in the polymerization reaction. Said substances are preferably saturated fatty acids and fatty acid derivatives. The invention also relates to methods for producing such medical products, and to the use of the same.
In addition to HIVST and mHealth access, participants in Arm 3 will also be in enrolled in an 8-week Creating Futures program. This manualized program was developed with youth in South Africa and adapted for the Kenyan context (manual is appended). Topics within the Creating Futures program include: 1) introduction and situating self; 2) sustainable and social resources; 3) peer group meeting; 4) education and learning; 5) getting and keeping jobs; 6) income generating activities; 7) saving and coping with shocks; 8) reflection and looking ahead. This intervention aims to help participants think about, and plan for, their futures to assist them in making a living in the long term. Each workshop is facilitated by pairs of peer navigators and runs from 2-4 hours.
PURPOSE:To obtain a three-component pigment which develops color from yellow to flesh color, has excellent hiding properties, and is suitable as cosmetics, by a method wherein a monovalent alkali metal compd., a ferric compd. and titanium dioxide are mixed together in a specified ratio, and the mixture is calcined. CONSTITUTION:0.5-25wt% Monovalent alkali metal compd. (A) (e.g. potassium carbonat or lithium hydroxide), 0.5-25wt% ferric compd. (B) (e.g. ferric oxide or ferric carbonate) and 65-99wt% titanium dioxide (C) are mixed together. The resulting mixture is calcined at 500-1,000 deg.C to obtain the desired three- component pigment. The produced pigment has excellent dispersibility, dispersion stability and further excellent chemical resistance, and is suitable for use in cosmetics, paints, etc.
FIELD: organic chemistry, furan derivatives. SUBSTANCE: synthesis of 2-imino-4-hydroxyethylamino-5,5-dimethyl-2,5-dihydrofuran is carried out from aminoethanol and 3-hydroxy-3-methyl-1-butyne-1-carbonitrile in ethanol medium. The yield is 90%, m. p. is 144-146 C, empirical formula is CHNO. The end product shows activity that is identical with the known analgetics and its antiinflammatory activity exceeds that of brufen (therapeutic index is 8.7 as compared with 6.2). Toxicity of the end product and brufen: 435 and 282 mg/kg, respectively. EFFECT: improved method of synthesis, increased yield and enhanced activity. 2 tbl
Sepsis has been a major health problem for centuries and it is still the leading cause of hospital deaths. Several studies in the past decades have identified numerous biochemical abnormalities in severe cases, and many of these studies provide evidence of the perturbation of the hemostatic system. This can result in complications, such as disseminated intravascular coagulation that can lead to multiorgan failure. Nevertheless, large clinical studies have demonstrated that the simple approach of inhibiting the coagulation processes by any means fails to provide significant improvement in the survival of septic patients. A cause of this failure could be the fact that in sepsis the major clinical problems result not primarily from the presence of the infective agent or enhanced coagulation but from the complex dysregulated systemic host response to pathogens. If this overt reaction is not fully deciphered, appropriate interference is highly unlikely and any improvement by conventional therapeutic interventions would be limited. Cellular activation in sepsis can be targeted by novel approaches like inhibition of the heterotypic cellular interactions of blood cells by targeting surface receptors or posttranscriptional control of the hemostatic system by noncoding ribonucleic acid (RNA) molecules. Stable RNA molecules can affect the expression of several proteins. Thus, it can be anticipated that modulation of microRNA production would result in a multitude of effects that may be beneficial in septic cases. Here, we highlight some of the recent diagnostic possibilities and potential novel routes of the dysregulated host response.
The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain has numerous O-glycosylation sites. Domain 2 is a repeat domain comprising homologous repeat units of 156 amino acids. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units are the sites of OC125 and M11 antibody binding. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail.
Framed within a diathesis-stress model of disease, the primary objective of this research is to determine a pathophysiological role of estradiol (E2) variability in the context of severe psychosocial stress exposure in regulating neurophysiological correlates of affective state change in girls (ages 11-14) during the pubertal transition (i.e., Tanner developmental stages 3 or 4). The rationale for examining E2 variability as a diathesis for mood impairment is twofold. First, sensitivity to hormonal flux during specific reproductive events has been shown to trigger affective symptoms in susceptible women, and second, E2 is a powerful neuroregulator of neural networks implicated in depression.

55 peripubertal girls undergoing a healthy pubertal transition will be recruited for the study. Over an 8-week period, depression symptoms (Center for Epidemiological Studies Depression Scale for Children (CES-DC)), anxiety (State Trait Anxiety Inventory (STAI-C)), and perceived stress (perceived stress scale (PSS)), and salivary E2 measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) will be assessed on a weekly basis. An electroencephalogram (EEG) during an emotional go/no-go task will be performed after the 8-week collection period to probe neurophysiological correlates of maturing fronto-limbic circuitry and assess key domains of cognitive and emotional processing impacted by the hormonal milieu. At the follow-up visit, an acute psychosocial stressor (Trier Social Stress Test) will be administered to examine cortisol and autonomic stress reactivity. The central hypothesis of the proposed research is that the amplitude and synchrony of frontal neural oscillations evoked during the cognitive-affective processing paradigm, and cortisol reactivity to the psychosocial stressor will partially mediate the relationship between greater E2 variability and elevated depression symptoms in peripubertal girls, and this relationship will be particularly strong in girls who have experienced recent (within six months) psychosocial stress.
Cases of hypoglycemia in non-diabetic patients treated with sulfamethoxazole and trimethoprim are seen rarely, usually occurring after a few days of therapy. Patients with renal dysfunction, liver disease, malnutrition or those receiving high doses of sulfamethoxazole and trimethoprim are particularly at risk.

Hematological changes indicative of folic acid deficiency may occur in elderly patients or in patients with preexisting folic acid deficiency or kidney failure. These effects are reversible by folinic acid therapy.

Trimethoprim has been noted to impair phenylalanine metabolism, but this is of no significance in phenylketonuric patients on appropriate dietary restriction.

As with all drugs containing sulfonamides, caution is advisable in patients with porphyria or thyroid dysfunction.
PURPOSE:To obtain a cosmetic having beautiful transparent appearance and excellent storage stability and giving the skin with high moisture-retaining property, softness and moist feeling, by compounding triethyl citrate with a liquid polyhydric alcohol and a liquid fatty acid ester having branched chain. CONSTITUTION:The objective cosmetic can be produced by compound (A) triethyl citrate, (B) a liquid polyhydric alcohol, e.g. ethylene glycol, glycerol or sorbitol and (C) a liquid fatty acid ester having branched chain, e.g. 2- ethylhexanoic acid triglyceride or isopropyl myristate. The amounts of the components A, B and C are 5-90wt.%, 5-80wt.% and 5-90wt.% respectively and the sum of A and C is 20-95wt.% based on the final composition. The feeling such as moistness, refreshingness, etc., can be further improved by the addition of at most 5wt.% of water.